Author:
Mills Roger M.,Berkowitz Richard D.,Damaraju C.V.,Jennings Lisa K.,Wildgoose Peter
Reference27 articles.
1. In vitro and in vivo studies of the novel antithrombotic agent BAY 59–7939 − an oral, direct Factor Xa inhibitor;Perzborn;J Thromb Haemost,2005
2. Rivaroxaban: a new oral Factor Xa inhibitor;Perzborn;Arterioscler Thromb Vasc Biol,2010
3. Metabolism and excretion of rivaroxaban, an oral, direct Factor Xa inhibitor, in rats, dogs and humans;Weinz;Drug Metab Dispos,2009
4. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59–7939, an oral, direct Factor Xa inhibitor;Kubitza;Clin Pharmacol Ther,2005
5. Safety, pharmacodynamics, and pharmacokinetics of BAY 59–7939 – an oral, direct Factor Xa inhibitor – after multiple dosing in healthy male subjects;Kubitza;Eur J Clin Pharmacol,2005
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献